New publication : A new class of molecule targeting the NEET family of proteins

Published on 19/11/2020

ENYO is proud to share international collaborative study showing the development of MITO-C (one compound of EYP002 series) a new class of molecule targeting the
NEET family of protein. This work co-led by Etienne Morel (INEM, Paris, France) and Benoît de Chassey (ENYO Pharma, Lyon France) and sponsored by ENYO Pharma nicely shows that MITO-C (one compound of EYP002 series) modulates mitochondria morphogenesis and stabilizes ER-Mitochondria contact sites. This seminal fundamental results opens potential indications that go beyond infectious diseases e.g. metabolic or neurodegenerative diseases. Publication here

Read next in 'Latest news'

• La Phase 2
• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)